Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | CDC25B | P30305 | 1/20 | 0.41 |
| ▸ | PDE3B | Q13370 | 4/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 4/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | CASP1 | P29466 | 2/20 | 0.33 |
| ▸ | BLM | P54132 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CASP7 | P55210 | 1/20 | 0.33 |
| ▸ | FEN1 | P39748 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.32 |
| ▸ | KDM4A | O75164 | 1/20 | 0.32 |
| ▸ | KDM4B | O94953 | 1/20 | 0.32 |
| ▸ | KDM5C | P41229 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30227719 | 1.00 | MAOA (0.42) | MAOAMAOBCDC25BPDE3BPDE3A | |
| SCHEMBL2657717 | 0.83 | MAOA (0.42) | MAOAMAOBCDC25BPDE3BPDE3A | |
| SCHEMBL23645371 | 0.81 | MAOA (0.41) | MAOAMAOBCDC25BPDE3BPDE3A | |
| Hydrochloric Acid SCHEMBL7086045 | 0.81 | MAOA (0.41) | MAOAMAOBCDC25BPDE3BPDE3A | |
| Octane SCHEMBL5764314 | 0.70 | KDM4E (0.38) | CYP3A4KDM4EKDM4CGSK3B | |
| SCHEMBL113314 | 0.70 | GSK3B (0.40) | MAOAMAOBCDC25BMAPTTP53 | |
| SCHEMBL29394879 | 0.70 | GSK3B (0.40) | MAOAMAOBCDC25BMAPTTP53 | |
| SCHEMBL3709717 | 0.69 | MAOA (0.38) | MAOAMAOBCDC25BPDE3BPDE3A | |
| Hydrochloric Acid SCHEMBL20475155 | 0.68 | GSK3B (0.39) | MAOAMAOBCDC25BMAPTTP53 | |
| SCHEMBL30130240 | 0.65 | SIGMAR1 (0.36) | MAOAMAOBPDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023057882-A1 | COMBINATIONS OF AZALACTAM COMPOUNDS WITH A PD-1 AXIS BINDING ANTAGONIST FOR THE TREATMENT OF CANCER | PFIZER INC. (US) | 2023-04-13 | — | — | WO | claimed |
| EP-4143186-A1 | AZALACTAM COMPOUNDS AS HPK1 INHIBITORS | Pfizer Inc. (US) | 2023-03-08 | — | — | EP | claimed |
| WO-2021220185-A1 | AZALACTAM COMPOUNDS AS HPK1 INHIBITORS | PFIZER INC. (US) | 2021-11-04 | — | — | WO | claimed |
| US-20260085045-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI HANSOH BIOMEDICAL CO LTD (CN) | 2026-03-26 | — | — | US | disclosed |
| WO-2025264837-A1 | NAPHTHYRIDINE GPR52 MODULATORS AND METHODS OF USE THEREOF | LIEBER INSTITUTE, INC. (US) | 2025-12-26 | — | — | WO | disclosed |
| US-12441725-B2 | ISO-citrate dehydrogenase (IDH) inhibitor | ZHEJIANG METON PHARMACEUTICAL CO., LTD (CN) | 2025-10-14 | — | — | US | disclosed |
| US-12240836-B2 | Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof | DONG-A ST CO., LTD. (KR) | 2025-03-04 | — | — | US | disclosed |
| US-20240197703-A1 | Azalactam Compounds as HPK1 Inhibitors | PFIZER INC. (US) | 2024-06-20 | — | — | US | disclosed |
| US-20240116917-A1 | ISO-CITRATE DEHYDROGENASE (IDH) INHIBITOR | ZHEJIANG METON PHARMACEUTICAL CO., LTD (CN) | 2024-04-11 | — | — | US | disclosed |
| US-20240025884-A1 | COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | DONG-A ST CO., LTD. (KR) | 2024-01-25 | — | — | US | disclosed |
| EP-3880676-B1 | 2,3-DIHYDRO-1H-PYRROLO[3,4-C]PYRIDIN-1-ONE DERIVATIVES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | PFIZER (US) | 2023-08-02 | — | — | EP | disclosed |
| US-20220401424-A1 | Azalactam Compounds as HPK1 Inhibitors | PFIZER INC. (US) | 2022-12-22 | — | — | US | disclosed |
| WO-2021220185-A1 | AZALACTAM COMPOUNDS AS HPK1 INHIBITORS | PFIZER INC. (US) | 2021-11-04 | — | — | WO | disclosed |
| US-11142525-B2 | Azalactam compounds as HPK1 inhibitors | PFIZER INC. (US) | 2021-10-12 | — | — | US | disclosed |
| EP-3880676-A1 | 2,3-DIHYDRO-1H-PYRROLO[3,4-C]PYRIDIN-1-ONE DERIVATIVES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | Pfizer Inc. (US) | 2021-09-22 | — | — | EP | disclosed |
| US-20200172539-A1 | Azalactam Compounds as HPK1 Inhibitors | PFIZER INC. (US) | 2020-06-04 | — | — | US | disclosed |
| WO-2020100027-A1 | 2,3-DIHYDRO-1H-PYRROLO[3,4-C]PYRIDIN-1-ONE DERIVATIVES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | PFIZER INC. (US) | 2020-05-22 | — | — | WO | disclosed |
| EP-2885300-A1 | TRIS(HETERO)ARYLPYRAZOLES AND USE THEREOF | AiCuris GmbH & Co. KG (DE) | 2015-06-24 | — | — | EP | disclosed |
| WO-2014027112-A1 | TRIS(HETERO)ARYLPYRAZOLES AND USE THEREOF | AICURIS GMBH & CO. KG (DE) | 2014-02-20 | — | — | WO | disclosed |
| WO-1998042666-A1 | NOVEL 3,4-DIALKOXYPHENYL DERIVATIVES AND THE USE THEREOF | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 1998-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116917-A1 | ISO-CITRATE DEHYDROGENASE (IDH) INHIBITOR | IDH2, IDH3A, IDH1 | MAOA 4614/4885MAOB 4568/4885CDC25B 890/4885 |
| US-20220401424-A1 | Azalactam Compounds as HPK1 Inhibitors | CDKN1A, HIPK1, CMPK1 | MAOA 3172/4885MAOB 3159/4885CDC25B 590/4885 |
| US-20200172539-A1 | Azalactam Compounds as HPK1 Inhibitors | CDKN1A, HIPK1, CMPK1 | MAOA 2353/4885MAOB 3949/4885CDC25B 919/4885 |
| US-12240836-B2 | Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof | EIF2AK4, GCN1, GCGR | MAOA 2614/4885MAOB 2265/4885CDC25B 3172/4885 |
| US-11142525-B2 | Azalactam compounds as HPK1 inhibitors | CDKN1A, HIPK1, CMPK1 | MAOA 2353/4885MAOB 3949/4885CDC25B 919/4885 |
| US-20260085045-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | NPR1, CBR1, NAT1 | MAOA 341/4885MAOB 460/4885CDC25B 3112/4885 |
| US-20240025884-A1 | COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | EIF2AK4, GCN1, GCGR | MAOA 2614/4885MAOB 2265/4885CDC25B 3172/4885 |
| US-20240197703-A1 | Azalactam Compounds as HPK1 Inhibitors | CDKN1A, HIPK1, CMPK1 | MAOA 3172/4885MAOB 3159/4885CDC25B 590/4885 |
| US-12441725-B2 | ISO-citrate dehydrogenase (IDH) inhibitor | IDH2, IDH3A, IDH1 | MAOA 4614/4885MAOB 4568/4885CDC25B 890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.